Tekturna, a direct renin inhibitor, is indicated for the treatment of hypertension in patients aged 6 years and older. It works by decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to angiotensin I. During treatment, the effect of increased renin levels is blocked so that PRA, angiotensin I, and angiotensin II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.
Aliskiren hemifumarate tablets will be made available by Prasco, LLC in 150mg and 300mg strengths. Noden will continue to manufacture the brand products Tekturna and Tekturna HCT (aliskiren and hydrochlorothiazide).
For more information visit PDL.com.
This article originally appeared on MPR